Article (Scientific journals)
Preclinical evaluation of topically-administered PEGylated Fab’ lung toxicity
Freches, D.; Rocks, Natacha; Patil, H. P. et al.
2019In International Journal of Pharmaceutics: X, 1
Peer Reviewed verified by ORBi
 

Files


Full Text
Freches Int J Pharmaceutics 2019 - Toxicity of PEGylated Fab.pdf
Publisher postprint (5.15 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Alveolar macrophages; Lung toxicity; Monoclonal antibodies; PEGylation; Pulmonary drug delivery; Article; J774A1 cell line
Abstract :
[en] PEGylation is a promising approach to increase the residence time of antibody fragments in the lungs and sustain their therapeutic effects. However, concerns arise as to the potential pulmonary toxicity of antibody fragments conjugated to high molecular weight (HMW) polyethylene glycol (PEG), notably after repeated administrations, and the possibility of PEG accumulation in the lungs. The purpose of this proof-of-concept study is to give insights about the safety of lung administration of a Fab’ anti-IL17A antibody fragment conjugated to two-armed 40 kDa PEG (PEG40). The presence of the PEG40 moiety inside alveolar macrophages remained stable for at least 24 h after intratracheal administration of PEG40-Fab’ to mice. PEG40 was then progressively cleared from alveolar macrophages. Incubation of PEG40 alone with macrophages in vitro did not significantly harm macrophages and did not affect phagocytosis or the production of inflammatory markers. After acute or chronic administration of PEG40-Fab’ to mice, no signs of significant pulmonary toxicity or inflammatory cell accumulation were observed. A vacuolization of alveolar macrophages not associated with any inflammation was noticed when PEG40, PEG40-Fab’, or unPEGylated Fab’ were administered. To conclude this preliminary proof of concept study, acute or repeated pulmonary administrations of PEGylated Fab’ appear safe in rodents. © 2019 The Authors
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Freches, D.;  Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium
Rocks, Natacha ;  Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Patil, H. P.;  Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium
Perin, Fabienne ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Van Snick, J.;  Ludwig Cancer Research Ltd, Brussels Branch, Avenue Hippocrate 74, UCLouvain, 7459, Brussels, B-1200, Belgium
Vanbever, R.;  Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium
Cataldo, Didier  ;  Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Language :
English
Title :
Preclinical evaluation of topically-administered PEGylated Fab’ lung toxicity
Publication date :
2019
Journal title :
International Journal of Pharmaceutics: X
eISSN :
2590-1567
Publisher :
Elsevier B.V.
Volume :
1
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 26 April 2021

Statistics


Number of views
64 (7 by ULiège)
Number of downloads
43 (6 by ULiège)

Scopus citations®
 
5
Scopus citations®
without self-citations
3
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi